The glomerular capillary wall is a three-layered filtration barrier (from blood to urine):

1. Fenestrated endothelium — endothelial cells with pores (~70–100 nm) that allow plasma to contact the GBM; these pores are covered by a glycocalyx that repels negatively charged proteins
2. Glomerular Basement Membrane (GBM) — the acellular "sieve" composed of extracellular matrix proteins
3. Podocytes (visceral epithelial cells) — specialised cells with interdigitating foot processes connected by slit diaphragms (~40 nm gaps) that provide the final size-selective barrier

The GBM is composed of:

• Type IV collagen — the structural backbone; forms a meshwork of triple-helical protomers
• Laminin — cross-links the collagen network
• Nidogen (entactin) — bridges laminin and collagen
• Heparan sulphate proteoglycans (e.g., agrin, perlecan) — provide the negative charge barrier that repels albumin (pI ~4.7, negatively charged at physiological pH)

Type IV collagen has six α-chains (α1–α6), encoded by COL4A1 through COL4A6 genes:

During glomerulogenesis, the immature GBM initially contains α1α1α2 networks. As the glomerulus matures, there is a developmental switch to the mature α3α4α5 network. This mature network is:

• More heavily cross-linked (resistant to proteolysis)
• Contains the critical α3, α4, and α5 chains needed for normal GBM thickness and function

Mutations in the type 4 collagen genes cause both Alport syndrome and TBMD ^[1]

• Normal adult GBM thickness: 300–400 nm ^[2]
• TBMD GBM thickness: 150–225 nm (roughly half of normal) ^[2]
• In children, the GBM is physiologically thinner and matures with age, making diagnosis in young children more difficult

• TBMD is due to heterozygous COL4A3/COL4A4 mutations, i.e., 'carriers' of autosomal recessive (AR) Alport syndrome ^[2]
• Inheritance: Autosomal Dominant (AD) — because a single heterozygous mutation is sufficient to produce the phenotype ^[3]
• Over 100 different pathogenic variants have been identified in COL4A3 and COL4A4
• A minority of patients with clinical TBMD have no identifiable COL4A3/4 mutation, suggesting other genetic or non-genetic causes of GBM thinning

Key points along this cascade:

1. Haploinsufficiency: One normal allele produces ~50% of the α-chain. This is enough to assemble a continuous GBM (unlike Alport syndrome where the network is catastrophically disrupted), but the GBM is quantitatively thinner.

2. Localised transient ruptures: The thin GBM is more susceptible to small mechanical tears from normal glomerular filtration pressures. These tears are focal, transient, and self-healing — which is why haematuria can be intermittent ^[2].

3. Heterozygous defect is sufficient to disrupt GBM architecture to result in haematuria, but not sufficient to provoke the secondary processes that result in proteinuria and progressive CKD as in Alport syndrome ^[2]. This is the crucial distinction — in Alport syndrome, the severely disrupted GBM triggers podocyte injury, mesangial proliferation, tubulointerstitial fibrosis, and progressive glomerulosclerosis. In TBMD, the GBM is thin but architecturally intact enough that these downstream cascades usually do not occur.

• The GBM's charge barrier (from heparan sulphate proteoglycans) and the podocyte slit diaphragm remain largely intact in TBMD
• The thinning creates holes big enough for RBCs to occasionally squeeze through during transient ruptures, but the overall protein permeability is not significantly increased
• When proteinuria does develop (a minority), it suggests either:
  • A second genetic hit
  • Superimposed secondary glomerular disease (e.g., FSGS, IgAN)
  • Haemodynamic stress (hypertension, hyperfiltration)

The modern "COL4A nephropathy" classification (2021 Kashtan revised nomenclature) places TBMD and Alport syndrome on a continuum:

Three classic causes of isolated glomerular haematuria ^[1][3]:

1. IgA nephropathy
2. Alport syndrome
3. Thin basement membrane disease

Isolated glomerular haematuria presents with normal GFR, no evidence of systemic disease (normal RFT, normal BP), and may be associated with variable proteinuria, but usually < 1 g/day ^[3]

• Development of proteinuria (particularly > 0.5–1 g/day)
• Rising serum creatinine / declining GFR
• Hypertension
• It is unclear whether TBMD contributed to FSGS in these patients or is just an incidental finding ^[2]

This is a high-yield exam comparison ^[1][3]:

• Usually normal or shows only very minor, non-specific changes
• No mesangial proliferation, no crescent formation, no sclerosis (in uncomplicated TBMD)

• Negative — no immune complex deposits (IgA, IgG, IgM, C3 all negative)
• This is critical for distinguishing from IgA nephropathy (which shows mesangial IgA deposits)

• GBM thickness: 150–225 nm (cf. 300–400 nm in normal subjects) ^[2]
• The thinning is diffuse (involving most capillary loops), not focal
• No "basket-weave" lamellation or splitting (which characterises Alport syndrome)
• Podocyte foot processes are preserved (no effacement, unlike minimal change disease or FSGS)
• No electron-dense deposits

Electron microscopy is the best modality to visualize thin basement membrane disease ^[1]

• Urine microscopy: dysmorphic RBCs, acanthocytes, RBC casts
• Macroscopic haematuria of glomerular origin: painless, smoky brown / cola-coloured, NOT usually associated with clots (clots suggest lower urinary tract source) ^[3]

• Urine culture, cytology, AFB ^[3]
• Cystoscopy + upper tract imaging (KUB, USG, IVP/RP, CTU) for patients at risk of urological malignancy ^[3]

• Urine sediment, urine protein quantification, RFT ^[3]
• Selected serologies: C3/C4, ANA ^[3]

• Pure tone audiometry (PTA) for Alport syndrome ^[1][3]
• Molecular genetic testing for COL4A3-5 mutations in Alport syndrome or TBMD ^[3]
• Kidney biopsy: usually reserved for those with significant proteinuria (> 1 g/day) or other features ^[3]
• History + urinalysis of family members — a critical and often overlooked step ^[1]

Why it's in the differential: IgAN is the most common glomerulonephritis worldwide and a leading cause of isolated glomerular haematuria. It can present identically to TBMD with persistent microscopic haematuria.

Why it's in the differential: Alport syndrome shares the same genetic locus (COL4A genes) as TBMD and can present early with isolated haematuria before extrarenal features develop.

How can the three glomerular causes of haematuria be distinguished? → History + urinalysis of family members ^[1]

The features that favour TBMD over the other two:

• Gross haematuria unusual (< 10%) ^[1][3]
• AD inheritance; 30–50% with FHx of haematuria, but course generally BENIGN (often clinically silent) ^[3][4]
• No extrarenal features (no SNHL, no ocular disease)
• No progressive CKD (in the vast majority)
• D/dx: IgA nephropathy, Alport syndrome (FHx of renal failure, X-linked inheritance) ^[2]

This is the first and most important investigation. It answers the fundamental question: is this glomerular or non-glomerular haematuria?

Exclusion of non-glomerular haematuria: urine culture, cytology, AFB ^[3][4]

Why dysmorphic RBCs are pathognomonic of glomerular origin: When RBCs pass through the disrupted GBM, they undergo mechanical deformation (squeezed through tiny gaps in the thinned membrane). They then travel through the tubular system where the osmolality varies dramatically (from ~50 mOsm/kg in the dilute descending limb to ~1200 mOsm/kg in the medullary collecting duct). This osmotic stress causes membrane blebbing and creates the characteristic "acanthocyte" morphology — spiculated RBCs with vesicle-shaped protrusions. A threshold of > 5% acanthocytes in the urine sediment is highly specific for glomerular origin.

Basic laboratory investigations: blood for renal function test — urea and creatinine concentration ^[7]

This is a critical step in the diagnostic algorithm. The purpose is to exclude immune-mediated glomerulonephritides that could present with haematuria:

Exclusion of other glomerulopathies: urine sediment, urine protein quantification, RFT; selected serologies, e.g. C3/4, ANA ^[3][4]

Further investigations required include: immune marker panel — C3 and C4 for lupus nephritis; ANA and anti-dsDNA for lupus nephritis; ANCA for pauci-immune vasculitis; anti-GBM antibody for Goodpasture's syndrome ^[12]

Why this is done: PTA is a non-invasive, inexpensive screening test that can rapidly distinguish Alport syndrome from TBMD. In Alport syndrome, the defective α3-4-5 type IV collagen in the cochlear basilar membrane leads to ↓ adhesion of the Organ of Corti to the basilar membrane → high tone deafness ^[1]. This is ABSENT in TBMD because the heterozygous defect does not significantly affect cochlear function.

These extrarenal features are absent in TBMD. Their presence immediately shifts the diagnosis to Alport syndrome.

Exclusion of non-glomerular haematuria: cystoscopy + upper tract imaging (KUB, USG, IVP/RP, CTU) ^[3][4]

Renal biopsy is the definitive morphological investigation but is not routinely performed in TBMD. When done, it requires three components of analysis:

Most common biopsy finding [in glomerular haematuria workup] is IgA nephropathy, hereditary nephritis, non-specific glomerulonephritis and basement membrane diseases (e.g. benign familial haematuria) ^[6]

Practical biopsy procedure ^[9]:

• Patient prone, radiologist uses ultrasound guidance
• Lower pole of kidney targeted
• Multiple cores taken to ensure sufficient tissue for all three analyses (LM, IF, EM)
• At least 8–10 glomeruli needed for adequate assessment

Why genetic testing is increasingly preferred over biopsy:

1. Non-invasive (blood or saliva sample)
2. Can be done at any age (including children where GBM thickness norms are less established)
3. Identifies the exact mutation — allows genotype-phenotype correlation and prognostic counselling
4. Enables family screening — identify at-risk relatives before clinical manifestations
5. Essential for genetic counselling — clarify risk of offspring inheriting two mutations (AR Alport) if both parents are carriers

Current approach (2024–2026): Genetic testing with next-generation sequencing (NGS) panels covering COL4A3, COL4A4, and COL4A5 is becoming first-line in many centres, potentially replacing biopsy for diagnosis of COL4A nephropathies. The Alport Syndrome Classification Working Group recommends genetic testing as the primary diagnostic tool [KDIGO 2024 consensus].

History + urinalysis of family members is a critical and often underutilised investigation ^[1]:

Thin basement membrane disease runs in families as well ^[1]; 30–50% associated with FHx of haematuria, but generally BENIGN in course (often clinically silent) ^[3]

• TBMD itself does not pose a significant risk in pregnancy
• Haematuria may fluctuate but does not predict pre-eclampsia
• ACEI/ARB must be stopped if the patient conceives (teratogenic — see above)
• Alternative antihypertensives if BP control needed: labetalol, nifedipine, methyldopa
• Monitor for proteinuria (which may increase physiologically in pregnancy) — distinguish from pre-eclampsia

• TBMD carriers can donate a kidney, but require:
  • Thorough genetic counselling
  • Confirmation that they do NOT have early Alport syndrome
  • Understanding that donating a kidney with a thin GBM + becoming a single-kidney patient carries some theoretical risk
  • Long-term follow-up post-donation

This is the most clinically significant complication of TBMD, although it affects only a minority.

Prognosis is usually benign but a minority (5%) develop progressive CKD, especially those who have proteinuria or positive family history of CKD ^[2]

Why does a subset progress?

The mechanism is not completely understood, but the leading hypotheses are:

1. "Second hit" theory: The thin, fragile GBM is more susceptible to additional insults. Superimposed haemodynamic stress (hypertension), metabolic injury (diabetes, obesity), or a second glomerular disease (IgAN, FSGS) acts as a "second hit" on an already vulnerable GBM → accelerates glomerulosclerosis beyond what the second hit alone would cause.

2. Hyperfiltration injury: When some nephrons are damaged (by any cause), the remaining nephrons compensate by increasing single-nephron GFR (Brenner's hyperfiltration hypothesis). In a patient with an inherently thin GBM, this increased hydrostatic pressure across a fragile membrane may be particularly damaging, creating a positive feedback loop:

   Thin GBM → some nephron loss → compensatory hyperfiltration → more GBM stress → more nephron loss → progressive CKD

3. Genetic modifier effects: Some heterozygous COL4A3/4 mutations may be more pathogenic than others (e.g., truncating mutations vs missense). Additional polymorphisms in podocyte or GBM-related genes may modify the phenotype.

Risk factors for progression ^[2]:

• Proteinuria (the single most important predictor)
• Positive family history of CKD
• Hypertension
• Male sex (less certain, but mirrors Alport data)
• Specific mutation type (truncating > missense, though data are limited)

Proteinuria is both a complication and a prognostic marker in TBMD. When it develops, it signals that the GBM defect is now significant enough to disrupt not just the size barrier (allowing RBCs through) but also the functional permselectivity of the filtration barrier.

Pathophysiology of proteinuria in TBMD:

• The thin GBM may undergo focal areas of more severe structural disruption over decades
• Podocyte injury follows — as podocytes attempt to cover a structurally compromised GBM, they may undergo foot process effacement and eventually detach (podocytopenia)
• Loss of podocytes exposes the GBM → further protein leak → tubulointerstitial injury from protein overload in tubular fluid → fibrosis

Heterozygous defect is sufficient to disrupt GBM architecture to result in haematuria, but not sufficient to provoke secondary processes that result in proteinuria and progressive CKD as in Alport syndrome ^[2] — this holds true for the majority, but the minority who develop proteinuria are demonstrating that their particular mutation/context DOES provoke these secondary processes.

It is unclear whether TBMD contributed to FSGS in these patients or just an incidental finding ^[2]

This is a genuinely unresolved question in nephrology. Some TBMD patients who undergo biopsy for progressive proteinuria are found to have FSGS. Two interpretations exist:

The truth likely lies in between — TBMD may lower the threshold for developing FSGS in the presence of other risk factors (obesity, hypertension, hyperfiltration from reduced nephron mass).

Clinical significance: When FSGS is found on biopsy in a TBMD patient, management changes — immunosuppression (e.g., steroids ± calcineurin inhibitors) may be considered if the FSGS is thought to be primary, or ACEI/ARB + lifestyle modification if secondary.

Given that both TBMD (5–9% prevalence) and IgA nephropathy (the most common glomerulonephritis worldwide) are common, they can coexist in the same patient. When they do:

• The patient may present with features atypical for "pure" TBMD: synpharyngitic gross haematuria, heavier proteinuria, declining GFR
• Renal biopsy shows thin GBM on EM AND mesangial IgA deposits on IF
• Management must address the IgAN component (ACEI/ARB, possibly immunosuppression if MEST-C score warrants it)

Although gross haematuria is unusual ( < 10%) in TBMD ^[1], when it occurs it can cause:

ESKD is an extremely rare complication of "pure" TBMD. When it occurs, consider:

• Was the original diagnosis correct? Could this be Alport syndrome (autosomal dominant variant)?
• Is there a superimposed second glomerular disease?
• Are there non-renal accelerating factors (uncontrolled hypertension, diabetes)?

If ESKD does develop:

• Renal transplant: preferred option over dialysis ^[2]
• Should evaluate carefully for any co-existent Alport syndrome before living-related donor transplantation ^[2]

This is arguably the most important "complication" — not of the disease itself, but of diagnostic error. Because TBMD and Alport syndrome sit on a genetic continuum, there are scenarios where the initial diagnosis of TBMD is revised:

Why this matters clinically:

• A patient labelled "TBMD" who actually has mild Alport syndrome will not receive appropriate genetic counselling about offspring risk
• Related family members may not be screened for SNHL or ocular disease
• Living-related donor transplantation planning may be compromised

May develop de novo anti-GBM disease (3%) as some may express anti-α5 or anti-α3 Ab → attack graft kidney GBM → crescentic GN → plasmapheresis and cyclophosphamide ^[2]

Although this is primarily a complication of Alport syndrome patients post-transplant, it is discussed here because:

• Some TBMD patients who reach ESKD (especially those with large deletions encompassing the α3 or α4 encoding region) may never have expressed the normal α3α4α5 epitopes
• Upon receiving a normal donor kidney, their immune system encounters these "foreign" collagen epitopes for the first time → alloimmune anti-GBM antibody production

Pathophysiology from first principles:

Recipient has never produced normal α3/α4 collagen → immune system never developed tolerance
            ↓
Transplant introduces kidney with normal α3α4α5 GBM
            ↓
Recipient T cells recognise α3/α5 epitopes as foreign → help B cells
            ↓
B cells produce anti-α3 or anti-α5 IgG antibodies
            ↓
Antibodies bind linearly to graft GBM → complement activation → crescentic GN
            ↓
Rapid graft loss if untreated

Management: Plasmapheresis (remove circulating antibodies) + cyclophosphamide (suppress antibody production) + high-dose corticosteroids

Since ACEI/ARB is given for proteinuria > 0.5–1 g/day or hypertension or rising creatinine/declining GFR ^[2], the complications of these drugs are relevant:

Renal biopsy: only in selected patients who have proteinuria ^[2]. When performed, potential complications include: